The mechanism that causes the detachment of spermatozoa from the oviductal reservoir around the 6 time of ovulation remains to be elucidated. Because the cumulus cells of the bovine oocyte are 7 known to secrete progesterone (P4), and P4 has been shown to act upon cation channels of 8 spermatozoa (CatSper) in human spermatozoa, it was hypothesised that P4 could induce 9 hyperactivation due to an influx of extracellular calcium, and this would facilitate detachment of 10 spermatozoa from oviductal epithelial cells. Therefore, this study aimed to investigate the role and 11 mechanism of action of P4 in the release of spermatozoa from bovine oviduct epithelial cells (BOEC). 12
Introduction 39
Formation of a sperm reservoir in the isthmus of the oviducts plays a critical role in maintaining the 40 fertile lifespan of spermatozoa. Uncapacitated spermatozoa preferentially bind by the plasma 41 membrane overlying the acrosome to the ciliated surface of epithelial cells (Yanagimachi and Chang 42 1963; Lefebvre and Suarez 1996; Fazeli et al. 1999) , and bound spermatozoa have been shown to 43 have low intracellular Ca 2+ content, low tyrosine phosphorylation (Gualtieri et al. 2005) , intact 44 acrosomes (Gualtieri and Talevi 2000) and normal chromatin structure (Ellington et al. 1999) . Their 45 gradual release in response to the oviductal microenvironments surrounding bound spermatozoa 46 supplies the ampulla with a steady supply of functional spermatozoa while minimising the incidence 47 of polyspermy. The role of sperm capacitation in the detachment of spermatozoa from the oviductal 48 epithelium has been well described (Gadella and Boerke 2016; Miller 2018). Once capacitated 49 spermatozoa unbind, they lose their affinity for the oviductal epithelium (Gualtieri et al. 2005 ). 50
Moreover, it has been demonstrated that hyperactivation can induce the release of uncapacitated 51 spermatozoa, and these spermatozoa maintain the ability to rebind (Chang and Suarez 2012) . 52 Indeed, only mouse spermatozoa that exhibit hyperactivated motility detached from the oviductal 53 epithelium (Demott and Suarez 1992) , and those lacking the cation channel of spermatozoa 54 (CatSper) were unable to hyperactivate and failed to progress beyond the oviductal sperm reservoir 55 because they remained bound to the oviductal epithelium in vivo (Ho et al. 2009 from the oviductal epithelium can be induced by hyperactivation and the role, if any, that P4 may 96 play in the mechanism by which CatSper activation in bovine spermatozoa induces hyperactivation 97 and the release of spermatozoa from the oviductal epithelium remain unknown. To this end, the aim 98 of this study was to investigate the role and mechanism of action of P4 in the release of 99 spermatozoa from bovine oviduct epithelial cells. 100
Materials and methods 101

Chemicals and reagents 102
Unless stated otherwise, all chemicals and reagents were purchased from Sigma-Aldrich Ireland. 103
Sperm preparation 104
Frozen-thawed straws from three different Holstein-Friesian bulls were thawed at 37°C and pooled 105
to minimise interbull variability. Only samples with a post-thaw motility >60% were used. Sperm 106 concentration was determined using a Neubauer chamber and samples were diluted to 40 × 10 6 107 spermatozoa mL -1 in Tyrode's albumin lactate pyruvate (TALP) medium. This medium consists of 99 108 mM NaCl, 3.1 mM KCl, 25 mM NaHCO 3 , 0.4 mM NaH 2 PO 4 , 1.1 mM MgCl 2 , 2 mM CaCl 2 , 10 mM 109 HEPES, 25.4 mM Na lactate, 1 mM Na-pyruvate and 6 mg mL -1 bovine serum albumin (BSA). 110
Assessment of hyperactivation 111
Hyperactivation was assessed subjectively using a phase contrast microscope (CX41; Olympus) fitted 112 with a heated stage (37°C) at a magnification of ×400. Aliquots (200 μL) of treated spermatozoa 113
were incubated for 10 min in 5% CO 2 at 37°C. After incubation, a 10-μL droplet of sample was placed 114 on a prewarmed slide with a coverslip for evaluation. were washed, recollected in 1 mL PBS and were centrifuged at 200g for 1 min at 37°C. The 135 supernatant was removed after centrifugation and 1 mL M199 culture medium supplemented with 136 10% fetal bovine serum and 0.5% gentamycin was added to the pellet. The BOECs were then 137 incubated in a 5% CO 2 incubator at 37.5°C for 1 h to allow the formation of everted vesicles with 138 apical ciliated surfaces orientated outwards (Ignotz et al. 2007 ). 139
Sperm samples were stained with a 10 µg mL -1 Hoechst 33342 solution, centrifuged twice at 300g 140
for 5 min at 37°C and diluted to a concentration of 7.14 × 10 6 mL -1 using prewarmed TALP medium, 141
after which they were added to a 24-well plate in 140-μL aliquots. After incubation with M199 142 culture medium, the BOEC explants were washed and centrifuged at 200g for 5 min at 37°C with PBS 143 (5 mL). After this centrifugation, the supernatant was discarded, and 20 µL pellet (BOEC explants in a 144 minimum volume of PBS) was added to each aliquot of spermatozoa in the 24-well plate. 145
Spermatozoa and BOECs were coincubated for 30 min at 37.5°C and 5% CO 2 , after which loosely 146 bound spermatozoa were removed from the samples by gently pipetting through two 75-μL droplets 147 of TALP. Each sample was assessed for bound sperm density, which confirmed equal binding in all 148 wells. Then, spermatozoa and BOECs were treated with P4 or the range of either agonists and 149
antagonists for 30 min at 37.5°C and 5% CO 2 . After incubation, loosely bound and unbound 150 spermatozoa were removed by gently pipetting through two 75-μL droplets of TALP. A 10-μL droplet 151 was then placed on a prewarmed slide and covered with a coverslip. Slides were viewed on a heated 152 stage (37°C) at ×400 under a combination of transmitted and epifluorescence lighting using a 153 fluorescent microscope (BX60; Olympus). alone, 2 μM NNC alone, 5 μM mibefradil alone, 10 nM P4 + 5 μM mibefradil, 10 nM P4 + 2 μM NNC, 200 10 nM P4 + 5 μM mibefradil + 2 μM NNC and 10 nM P4 + 2.5 mM EGTA. All treatments were 201 assessed for bound sperm density after treatment as described above, and three replicates were 202 completed. 203
Experiment 1c: effects of P4 and extracellular Ca 2+ on hyperactivation after detachment from BOECs 204
This experiment was performed to determine the percentage hyperactivation of spermatozoa 205 detached from BOECs after the following treatment: no treatment control, 10 nM P4 alone, 2 μM 206 NNC alone, 5 μM mibefradil alone, 10 nM P4 + 5 μM mibefradil, 10 nM P4 + 2 μM NNC, 10 nM P4 + 5 207 μM mibefradil + 2 μM NNC and 10 nM P4 + 2.5 mM EGTA. The treatments chosen were the same as 208 those assessed in Experiments 1a and 1b. For this experiment, after the 30 min incubation of sperm 209 bound to BOECs with P4 and Ca 2+ channel antagonists, a 10-μL aliquot was collected from each well 210 and the percentage hyperactivation of spermatozoa detached from BOECs was determined as 211 described above. The assessor was blinded to the treatments being assessed, and four replicates 212 were completed. 213
Experiment 2: effects of P4 receptor antagonists on the action of P4 214
The aim of this experiment was to investigate the mechanism of P4 action on bovine spermatozoa. It 215 was hypothesised that P4 acts on spermatozoa through non-genomic pathways to initiate the influx 216
of Ca 2+ . AG205 is a P4 receptor membrane component 1 spermatozoa, the effects of P4 receptor antagonists in the presence of P4 were assessed on 222 hyperactivated spermatozoa and on detached spermatozoa from BOECs. 223
Experiment 2a: effects of P4 receptor antagonists on P4-induced hyperactivation 224
The aim of this experiment was to investigate whether P4-induced hyperactivation is mediated 225 through a membrane-bound P4 receptor. An initial dose-response experiment was performed for 226 both mifepristone and AG205 and the optimum concentration with the greatest effect on 227
counteracting the action of P4 on sperm hyperactivation was chosen. A vehicle control was 228 performed for mifepristone because it was dissolved in DMSO. In the case of mifepristone, the 229 following treatments were assessed: no treatment control, 10 nM P4 alone and 10 nM P4 + 230 mifepristone (40 and 400 nM and 4 and 400 μM). In the case of AG205, the following treatments 231
were assessed: no treatment control, 10 nM P4 alone and 10 nM P4 + AG205 (5, 10, 20, 30 and 40 232 μM). Hyperactivation responses of spermatozoa were analysed using the methods described above. 233
From each of the two dose-response experiments above, the optimum concentration of each drug 234 was chosen and assessed in one experiment to confirm their effects. Treatments included a no 235 treatment control, 10 nM P4 alone, 400 nM mifepristone alone, 10 μM AG205 alone, 400 nM 236 mifepristone + 10 μM AG205, 10 nM P4 + 400 nM mifepristone, 10 nM P4 + 10 μM AG205 and 10 237 nM P4 + 400 nM mifepristone + 10 μM AG205. All treatments were assessed in a blinded manner, 238
and three replicates were completed. 239
Experiment 2b: effects of P4 and P4 receptor antagonists on the detachment of spermatozoa from 240
BOECs 241
It was hypothesised that the action of P4 in the detachment of spermatozoa from BOECs would be 242 suppressed through the use of P4 receptor antagonists. Bound spermatozoa were treated with a no 243 treatment control, 10 nM P4 alone, 400 nM mifepristone alone, 10 μM AG205 alone, 400 nM 244 mifepristone + 10 μM AG205, 10 nM P4 + 400 nM mifepristone, 10 nM P4 + 10 μM AG205 and 10 245 nM P4 + 400 nM mifepristone + 10 μM AG205. The number of bound spermatozoa remaining after 246 each treatment was assessed. The assessor was blinded to the treatments being assessed, and three 247 replicates were completed. 248
Experiment 2c: effects of P4 and P4 receptor antagonists on hyperactivation after the detachment of 249 spermatozoa from BOECs 250
This experiment was performed to determine the percentage hyperactivation of spermatozoa 251 detached from BOECs after the following treatments: no treatment control, 10 nM P4 alone, 400 nM 252 mifepristone alone, 10 μM AG205 alone, 400 nM mifepristone + 10 μM AG205, 10 nM P4 + 400 nM 253 mifepristone, 10 nM P4 + 10 μM AG205 and 10 nM P4 + 400 nM mifepristone + 10 μM AG205. The 254 treatments chosen were the same as assessed in Experiments 2a and 2b. For this experiment, after 255 the 30 min incubation of spermatozoa bound to BOECs with P4 and P4 receptor antagonists, a 10-μL 256 aliquot was collected from each well and the percentage hyperactivation of the sperm detached 257
from BOECs was determined as described above. All treatments were assessed in a blinded manner, 258
and four replicates were completed. 259
Statistical analysis 260
All data were examined for normality of distribution and were analysed using IBM SPSS Software, 261
Version 22 (IBM Corp.). All data were normally distributed and thus univariate analysis of variance (ANOVA) was used. Post hoc tests were conducted using the Bonferroni test and two-sided P < 0.05 263 was considered significant. All results are reported as the mean ± s.e.m. 264
Results 265
Experiment 1: effects of P4 and extracellular Ca 2+ on hyperactivation and release of bound 266
spermatozoa from BOECs 267
Experiment 1a: effects of P4 and extracellular Ca 2+ on hyperactivation 268
Hyperactivated motility developed rapidly when spermatozoa were treated with P4, and there was 269 an effect of P4 treatments on hyperactivated motility (P < 0.001; Fig. 1 ). Increasing the concentration 270 of P4 increased sperm hyperactivation, with peak hyperactivation achieved at a concentration of 10 271 nM P4 (76.8 ± 3.0%; P < 0.001). The Ca 2+ channel antagonists NNC and mibefradil successfully 272 suppressed P4-induced hyperactivation, with concentrations of 2 μM NNC and 5 μM mibefradil 273 having the greatest antagonistic effect (P < 0.001; Fig. 2) ; these concentrations were used for 274 subsequent experiments. 275
Experiment 1b: effects of P4 and extracellular Ca 2+ on hyperactivation and the release of bound 276
spermatozoa from BOEC explants 277 P4 increased sperm hyperactivation (P < 0.001; Fig. 3 ) and stimulated the release of bound 278 spermatozoa from BOEC explants (P < 0.001; Fig. 3 ). Incubation of spermatozoa with the Ca 2+ 279 channel antagonists NNC and mibefradil alone had no effect on sperm hyperactivation (P > 0.05) 280 compared with control. However, incubation of spermatozoa with NNC and mibefradil alone had an 281 effect on the release of spermatozoa from BOEC explants (P < 0.01). NNC, mibefradil and EGTA 282 inhibited P4-induced hyperactivation (P < 0.001) and the release of spermatozoa from BOEC explants 283 induced by P4 (P < 0.001). The mean size of the vesicles was 0.00453 ± 0.000333 mm 2 . There were 284 no significant differences in the size of the vesicles among the different treatment groups (P = 285 0.176). 286
Experiment 1c: effects of P4 and extracellular Ca 2+ on hyperactivation after detachment from BOECs 287
We also determined hyperactivation of the spermatozoa detached from BOECs after the different 288 treatments. P4 alone significantly increased the percentage hyperactivation of spermatozoa released 289 from BOECs compared with the control group (52.7 ± 5.5% vs 16.0 ± 3.2% respectively; P < 0.001). In 290 the absence of P4, mibefradil and NNC did not affect hyperactivation (17.7 ± 4.7% and 20.7 ± 3.9% 291 respectively; P > 0.05). The hyperactivation shown by the spermatozoa released by P4 was inhibited 292
in the presence of EGTA (21.3 ± 2.2%; P < 0.001), mibefradil (27.0 ± 4.0%; P < 0.001), NNC (17.7 ± 293 2.3%; P < 0.001) and the combination of both Ca 2+ channel antagonists (14.0 ± 4.9%; P < 0.001). 294
Experiment 2: effects of P4 receptor antagonists on the action of P4 295
Experiment 2a: effects of P4 receptor antagonists on P4-induced hyperactivation 296
Both P4 receptor antagonists (AG205 and mifepristone) had an effect on P4-induced hyperactivated 297 motility (P < 0.001 and P < 0.001 respectively; Fig. 4 ). All concentrations of AG205 inhibited P4-298 induced hyperactivation (P < 0.001). Mifepristone (400 nM) had the greatest inhibitory effect against 299 P4 (P < 0.0001). Therefore, the lowest, most-effective concentrations of 10 μM AG205 (P < 0.0001) 300
and 400 nM mifepristone (P < 0.0001) were deemed optimum for use in subsequent experiments. 301
Experiment 2b: effects of P4 and P4 receptor antagonists on hyperactivation and the detachment of 302 spermatozoa from BOECs 303
There was an inhibitory effect of P4 receptor antagonists on sperm hyperactivation (P < 0.001) and 304 release of spermatozoa from BOEC explants (P < 0.01; Fig. 5 ). In the absence of P4, mifepristone and 305 AG205 alone or in combination did not affect hyperactivation (P > 0.05) or the release of 306 spermatozoa from BOECs (P > 0.05). Hyperactivation and the release of spermatozoa from BOEC 307 explants induced by P4 were inhibited in the presence of mifepristone (P < 0.001 and P < 0.05 308 respectively) and AG205 (P < 0.001 and P < 0.05 respectively). The combination of AG205 and 309 mifepristone had the highest significant effect in inhibiting the actions of P4 on both hyperactivation 310 and the release of spermatozoa from BOEC explants (P < 0.001 and P < 0.01 respectively). Bound 311 sperm density was not affected by P4 when incubated with both AG205 and mifepristone compared 312
with the control (P > 0.05). The mean size of the vesicles was 0.00371 ± 0.00020 mm 2 . There were no 313 significant differences in the size of the vesicles among the different treatment groups (P = 0.956). 314
Experiment 2c: effects of P4 and P4 receptor antagonists on hyperactivation after the detachment of 315
spermatozoa from BOECs 316 Hyperactivation of spermatozoa released from BOECs after the different treatments was 317 determined. P4 alone significantly increased the percentage hyperactivation of spermatozoa 318 released from BOECs compared with the control group (55.3 ± 7.4% and 13.8 ± 3.4% respectively; P < 319 0.001). In the absence of P4, mifepristone and AG205 alone or in combination had no effect on 320 hyperactivation (11.5 ± 3.0%, 12.0 ± 1.7% and 17.0 ± 4.3% respectively; P > 0.05). The 321 hyperactivation shown by spermatozoa released by P4 was inhibited in the presence of mifepristone 322 (18.3 ± 8.1%; P < 0.001), AG205 (11.8 ± 3.6%; P < 0.001) and the combination of both P4 receptor 323 antagonists (19.3 ± 2.2%; P < 0.001). 324
Discussion 325
The sequential release of fertile spermatozoa from the oviductal reservoir around the time of 326 ovulation helps deliver a supply of fertile spermatozoa to the ampulla and increases the chances of 327 successful fertilisation. Most studies to date have focused on the role of capacitation in the 328 mediation of sperm release and, to the best of the authors' knowledge, the present study is the first 329 published study to assess the effects of P4 on bovine sperm hyperactivation and associated 330 unbinding from the oviductal epithelium. The main findings of this study were that: (1) 331 hyperactivation stimulates a significant release of spermatozoa from BOECs; (2) hyperactivation of 332 bovine spermatozoa can be induced by P4 by a rapid non-genomic action; (3) P4 elicits its effect by 333 directly or indirectly acting on Ca 2+ channels, which facilitates the influx of extracellular Ca 2+ into the 334 cell; and (4) the action of P4 on spermatozoa, which was supressed by P4 receptor antagonists in this 335 dataset, infers the presence of a P4 membrane receptor. 336
The physiological factors that trigger the sequential release of spermatozoa from oviductal 337 reservoirs are not well understood. Interestingly, it has been found that P4 is more effective on the cell when it is present in the 400 extracellular milieu than when P4 is microinjected into the cytoplasm (Maller and Krebs 1977). It is 401 therefore proposed that the action of P4 on a surface receptor may trigger an influx of extracellular 402
Ca 2+ through CatSper (rapid rise), followed by a further CICR from intracellular stores (transient rise) 403 and stimulation of an intracellular pathway (i.e. phosphatidylinositol 3-kinase/AKT), meaning 404 phosphorylation of proteins in the sperm cell and thus leading to hyperactivated motility and the 405 development of the propulsive force to detach from the epithelial cells of the oviduct. Through this 406
proposed mechanism, the sperm cell still holds the essential surface molecules to reattach to the 407 oviduct cells on its journey to the oocyte. 408
In conclusion, this novel study has demonstrated that hyperactivation induced by P4 plays a role in 409 the detachment of bovine spermatozoa from BOEC explants, which is an indication of events 410 occurring in vivo. These findings indicate that the presence of extracellular Ca 2+ would be essential 411
for the sperm response to P4. In addition, we have presented evidence that the action of P4 is 412 mediated by a membrane P4 receptor, but the underlying mechanism that transduces the action of 413 P4 to intracellular pathways remains to be elucidated. Dissecting the physiological components of 414 the oviductal environment and their effects on sperm function will expand our understanding of 415 sperm binding, sequential release and their availability in a sufficient number at the site of 416 fertilisation close to the time of ovulation. This will lead to an optimisation of the use of semen 417 during AI, for example by reducing the sperm concentration per straw and thus increasing the 418 availability of straws of elite bulls. 419
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